Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Nordic Nanovector ASA ( (DE:8NN) ) has issued an announcement.
Thor Medical ASA has announced a Subsequent Offering following a successful private placement and retail offering, aiming to raise up to NOK 10 million. The offering, directed at eligible shareholders, allows for subscription of new shares at NOK 2.50 each, with the subscription period running from 26 June to 3 July 2025. This move is expected to strengthen the company’s financial position and support its operations in the radiopharmaceutical industry.
More about Nordic Nanovector ASA
Thor Medical ASA is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, providing a reliable, environmentally friendly, and cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. The company is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
Average Trading Volume: 2,278,123
Current Market Cap: NOK790.7M
See more data about 8NN stock on TipRanks’ Stock Analysis page.